Agonism at 5-HT2B receptors is not a class effect of the ergolines.
作者： Sven Jähnichen , Reinhard Horowski , Heinz H. Pertz
DOI: 10.1016/J.EJPHAR.2005.03.010
关键词:
摘要: Restrictive cardiac valvulopathies observed in Parkinson patients treated with the ergoline dopamine agonist pergolide have recently been associated efficacy of drug at 5-hydroxytryptamine2B (5-HT2B) receptors. To evaluate whether agonism 5-HT2B receptors is a phenomenon class ergolines, we studied receptor-mediated relaxation porcine pulmonary arteries to five ergolines which are used as antiparkinsonian drugs. Pergolide and cabergoline were potent full agonists this tissue (pEC50 8.42 8.72). Bromocriptine acted partial 6.86). Lisuride terguride, however, failed relax but potently antagonized 5-HT-induced (pKB 10.32 8.49). Thus, seems not be effect ergolines.
elsevier.com
sci-hub.se 参考文章(18)
David J. Kupfer, Floyd E. Bloom, Psychopharmacology: The Fourth Generation of Progress ,(1995)
Paul R. Hartig, John P. Patterson, David W. Robertson, Ilgar Abbaszade, Jeannine M. Hollis, Barry S. Brown, Lawrence W. Fitzgerald, Brian L. Largent, Gregory F. Hollis, Timothy C. Burn, Martha H. Corjay, Jung-Hui Sun, John R. Link, Paul C. Meunier, Patricia A. Valentine, Albert J. Robichaud, Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Molecular Pharmacology. ,vol. 57, pp. 75- 81 ,(2000)
Richard B. Rothman, Michael H. Baumann, Jason E. Savage, Laura Rauser, Ace McBride, Sandra J. Hufeisen, Bryan L. Roth, Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. ,vol. 102, pp. 2836- 2841 ,(2000) , 10.1161/01.CIR.102.23.2836
Jeffrey C Jerman, Stephen J Brough, Tracey Gager, Martyn Wood, Martyn C Coldwell, Darren Smart, Derek N Middlemiss, Pharmacological characterisation of human 5-HT2 receptor subtypes European Journal of Pharmacology. ,vol. 414, pp. 23- 30 ,(2001) , 10.1016/S0014-2999(01)00775-0
Canan G. Nebigil, Fabrice Jaffré, Nadia Messaddeq, Pierre Hickel, Laurent Monassier, Jean-Marie Launay, Luc Maroteaux, Overexpression of the Serotonin 5-HT2B Receptor in Heart Leads to Abnormal Mitochondrial Function and Cardiac Hypertrophy Circulation. ,vol. 107, pp. 3223- 3229 ,(2003) , 10.1161/01.CIR.0000074224.57016.01
Gordon S. Baxter, Olive E. Murphy, Thomas P. Blackburn, Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle British Journal of Pharmacology. ,vol. 112, pp. 323- 331 ,(1994) , 10.1111/J.1476-5381.1994.TB13072.X
Else Müller-Schweinitzer, Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors. Cardiovascular Drugs and Therapy. ,vol. 4, pp. 1455- 1460 ,(1990) , 10.1007/BF02026491
Guy Van Camp, Anja Flamez, Bernard Cosyns, Caroline Weytjens, Luc Muyldermans, Michel Van Zandijcke, Johan De Sutter, Patrick Santens, Pierre Decoodt, Christian Moerman, Danny Schoors, Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. The Lancet. ,vol. 363, pp. 1179- 1183 ,(2004) , 10.1016/S0140-6736(04)15945-X
Daniel V. Simula, William D. Edwards, Henry D. Tazelaar, Heidi M. Connolly, Hartzell V. Schaff, Surgical Pathology of Carcinoid Heart Disease: A Study of 139 Valves From 75 Patients Spanning 20 Years Mayo Clinic Proceedings. ,vol. 77, pp. 139- 147 ,(2002) , 10.4065/77.2.139
JACQUES SERRATRICE, PATRICK DISDIER, GILBERT HABIB, FRAN??OIS VIALLET, PIERRE-JEAN WEILLER, Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiology in Review. ,vol. 10, pp. 334- 336 ,(2002) , 10.1097/00045415-200211000-00005